Biopure restructures management, cuts staff by 25
This article was originally published in Clinica
Cambridge, Massachusetts-based blood substitute firm Biopure has announced a company restructure and initiated a corporate strategic realignment. Zafiris Zafirelis, previously CEO of MedQuest, has been appointed president and CEO, and a member of the board of directors. He replaces Thomas Moore, who left in February (see Clinica No 1097, p 15).
You may also be interested in...
A Phase III trial testing dapagliflozin in chronic kidney disease patients with and without diabetes was stopped early following a recommendation from an independent data monitoring committee.
Medtronic says that most of the clinical trials it is sponsoring are paused due to the pandemic, which means the completion of its PMA application for the Symplicity Spyral renal denervation system will be delayed.
Three-month results of the SPYRAL HTN-OFF MED pivotal trial show renal denervation with Medtronic’s Symplicity Spyral system significantly reduced blood pressure in hypertensive patients not taking anti-hypertensive medications.